Oncotarget

Research Papers:

E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines

Liming Li, Cui Xu, Jia Long, Danbei Shen, Wuqing Zhou, Qiyan Zhou, Jia Yang and Mingjun Jiang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:23930-23943. https://doi.org/10.18632/oncotarget.4525

Metrics: PDF 2445 views  |   HTML 3364 views  |   ?  


Abstract

Liming Li1,*, Cui Xu1,*, Jia Long1, Danbei Shen1, Wuqing Zhou1, Qiyan Zhou1, Jia Yang1 and Mingjun Jiang1

1 Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China

* These authors have contributed equally to this work

Correspondence to:

Mingjun Jiang, email:

Keywords: HPV16 E6 and E7, DNA methylation, immunoblot, cell viability and apoptosis, human cervical carcinoma cell lines

Received: April 26, 2015 Accepted: June 02, 2015 Published: June 19, 2015

Abstract

In SiHa and CaSki cells, E6 and E7-targeting shRNA specifically and effectively knocked down human papillomavirus (HPV) 16 E6 and E7 at the transcriptional level, reduced the E6 and E7 mRNA levels by more than 80% compared with control cells that expressed a scrambled-sequence shRNA. E6 and E7 repression resulted in down-regulation of DNA methyltransferase mRNA and protein expression, decreased DNA methylation and increased mRNA expression levels of tumor suppressor genes, induced a certain apoptosis and inhibited proliferation in E6 and E7 shRNA-infected SiHa and CaSki cells compared with the uninfected cells. Repression of E6 and E7 oncogenes resulted in restoration of DNA methyltransferase suppressor pathways and induced apoptosis in HPV16-positive cervical carcinoma cell lines. Our findings suggest that the potential carcinogenic mechanism of HPV16 through influencing DNA methylation pathway to activate the development of cervical cancer exist, and maybe as a candidate therapeutic strategy for cervical and other HPV-associated cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4525